期刊名称:Discussion Papers / Norwegian School of Economics and Business Administration
印刷版ISSN:0804-6824
出版年度:2006
卷号:2006
出版社:Bergen
摘要:We study the relationship between regulatory regimes and pharmaceutical firms’ pricing
strategies using a unique policy experiment from Norway, which in 2003 introduced a reference
price (RP) system called “index pricing” for a sub-sample of off-patent pharmaceuticals,
replacing the existing price cap (PC) regulation. We estimate the effect of the reform using
a product level panel dataset, covering the drugs exposed to RP and a large number of drugs
still under PC regulation in the time before and after the policy change. Our results show
that RP significantly reduced both brand-name and generic prices within the reference group,
with the effect being stronger for brand-names. We also identify a negative cross-price effect
on therapeutic substitutes not included in the RP-system. In terms of policy implications,
the results suggest that RP is more effective than PC regulation in lowering drug prices,
while the cross-price effect raises a concern about patent protection.